Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
|Articles|October 14, 2016
Pharmacy Week in Review: October 14, 2016
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Advertisement
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more. Our Week in Review is a can’t miss for the busy pharmacy professional.
Advertisement
Related to this article
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
With nearly 8 in 10 older adults misusing at least 1 OTC product, clearer counseling and labels could close the gap.
Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.
Cancer diagnoses among civilians exposed to 9/11 dust keep rising, with strained health programs struggling to meet growing needs.
With childhood immunization rates sliding and outbreaks accelerating, pharmacist-led counseling and vaccine administration can boost vaccination rates.
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
2
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
3
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
4
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
5